NEW YORK (GenomeWeb News) — Gene Logic today said it will help Merck Serono, a division of German drug maker Merck, identify alternative development paths for “several” undisclosed drug candidates.
 
All of the candidates were discontinued or “de-prioritized” in clinical trials for reasons other than safety, according to Gene Logic.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.